Lupin launches Mirabegron Extended-Release Tablets in the US
Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of $ 1,600 million in the US (IQVIA MAT July 2024)
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Pharma market
Gilead’s Livdelzi wins FDA approval, can challenge Ocaliva dominance in primary biliary cholangitis…
The approval could present a major challenge to Ocaliva (obeticholic acid), which was until recently the sole approved drug for…
Organon, Lilly expand migraine commercialisation agreement to 11 additional markets
Under the terms of the agreement, Organon will become the sole distributor and promoter of Emgality in the following additional…
Industry reports 88 deals worth $11.1B in July 2024: GlobalData
The lifesciences sector also reported 73 VC deals worth $2.5 billion
Industry reports 76 deals worth $5B in June 2023: GlobalData
The pharma industry reported 88 VC deals worth $2.5B in June 2024, compared to the last 12-month (June 2023 to May 2024) average…
71 per cent rise YoY during Q1 2024 in Biopharmaceutical M&A deals: GlobalData
GlobalData’s recent The State of the Biopharmaceutical Industry 2024 report reveals that the surveyed healthcare industry…
Credit profile of Indian pharma cos to remain healthy in FY2025 despite moderation in revenue…
Revenue growth to moderate to 8-10 per cent in FY2025, post a healthy 13-14 per cent YoY expansion in FY2024
Novel therapies to drive Crohn’s disease market growth across 8MM to $15 bn by 2032: GlobalData
An anticipated 11 assets in the late-stage pipeline will enter the CD market during the forecast period
LIC sells over two per cent stake in Sun Pharma for Rs 4,699 cr
Corporation's shareholding in Sun Pharma has decreased from 5.023 per cent to 3.012 per cent of the paid-up capital of the said…
Balaxi Pharma reports 23 per cent growth YoY during Q2FY23
Pharma revenue up 50 per cent with expanding contribution from Latin America